Trial reportScientific reports2019
Polymorphism A118G of opioid receptor mu 1 (OPRM1) is associated with emergence of suicidal ideation at antidepressant onset in a large naturalistic cohort of depressed outpatients.
Trial report in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Chinese herbal medicines for the treatment of depression: a systematic review and network meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Risk of Suicidal Behaviors and Antidepressant Exposure Among Children and Adolescents: A Meta-Analysis of Observational Studies.Frontiers in psychiatry · 2022Pooled it
- Durable recovery from amblyopia with donepezil.Scientific reports · 2023Trial
- Association Between Opioid Analgesics and Suicide Attempts: A Nationwide French Case-Crossover Study.CNS drugs · 2025Observational
- Let's Move Towards Precision Suicidology.Current psychiatry reports · 2025Review
- Molecular genetic basis of the primary emotions in young adults: an exploratory analysis of genetic polymorphisms across dopamine, serotonin, oxytocin, endogenous opioid, and neurotrophic factor pathways.Frontiers in pharmacology · 2025Article
- Mechanistic interplay of different mediators involved in mediating the anti-depressant effect of isoflavones.Metabolic brain disease · 2024Review
- Exploring the relationship between distress rumination, resilience, depression, and self-injurious behaviors among Chinese college athletes infected with COVID-19: a cross-sectional study.Frontiers in psychiatry · 2023Article
- Multiple suicide attempts associated with addiction to tramadol.Annals of general psychiatry · 2022Article
- Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review.Neurology international · 2021Review
- Genetic Vulnerability to Opioid Addiction.Cold Spring Harbor perspectives in medicine · 2021Review
- Sex-stratified gene-by-environment genome-wide interaction study of trauma, posttraumatic-stress, and suicidality.Neurobiology of stress · 2021Article
- Mechanisms Underlying the Anti-Suicidal Treatment Potential of Buprenorphine.Advances in drug and alcohol research · 2021Article
- Association Between the A118G Polymorphism of theNeuropsychiatric disease and treatment · 2021Article
- Polymorphisms of stress pathway genes and emergence of suicidal ideation at antidepressant treatment onset.Translational psychiatry · 2020Article
- The μ-opioid receptor gene A118G polymorphism is associated with insecure attachment in children with disruptive mood regulation disorder and their mothers.Brain and behavior · 2020Article
- The Role of Opiates in Social Pain and Suicidal Behavior.Current topics in behavioral neurosciences · 2020Review
- In Search of Reward Deficiency Syndrome (RDS)-free Controls: The "Holy Grail" in Genetic Addiction Risk Testing.Current psychopharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antidepressants have been the object of an international controversy for about thirty years. Some patients are inclined to develop suicidal ideation (SI) at antidepressant onset; this phenomenon is known as Treatment Emergent Suicidal Ideation (TESI), and it has conducted regulatory bodies to prompt warnings on antidepressants. Since, few studies have explored the pharmacogenomics of TESI. Given the growing body of evidence connecting the opioidergic system with suicidal behavior (particularly mu opioid receptor (MOR)), we decided to examine the relationship between two genetic polymorphisms (SNPs) in the opioidergic system and TESI in a sample of 3566 adult depressed outpatients. General practitioners and psychiatrists throughout France followed participants for 6 weeks after an initial prescription of tianeptine, an antidepressant treatment with mu agonism. Suicidal ideation was assessed with the item 10 of the Montgomery-Asberg Depression Rating Scale (item dedicated to SI) at baseline, and after 2 weeks, 4 weeks and 6 weeks. We analysed rs1799971 from the OPRM1 gene and rs105660 from the OPRK1 gene. Within the sample, 112 patients reported TESI while 384 did not. We found a significant association between AA genotype of rs1799971 and TESI even after adjustment for potential cofounders (OR = 1.93, 95% CI = [1.07; 3.49]; p-value = 0.03). On the other hand there were no significant association between rs1799971 and rs105560 with worsening of suicidal ideation or lifetime suicide attempts. Nevertheless, our results suggest a possible involvement of opioidergic system in TESI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.